Sectors
NKTR
Nektar Therapeutics
69.36
1 x 68.50
1 x 70.34
bid
ask
+
0.69
1.00%
332 @ 03:59 PM
70.00 +0.64 (0.92%)
| Ytd | 64.05% | |
| 1y | 183.33% |
68.41
day range
70.88
21.02
52 week range
109.00
| Open | 69.76 | Prev Close | 68.67 | Low | 68.41 | High | 70.88 | Mkt Cap | 2.31B |
| Vol | 460.55K | Avg Vol | 1.06M | EPS | -7.93 | P/E | -8.26 | Forward P/E | 34.01 |
| Beta | 1.14 | Short Ratio | 5.42 | Inst. Own | 80.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 67.11 | 200-d Avg | 62.43 | 1yr Est | 153.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-06 | 2026-06 | -1.94 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | -1.58 | -1.82 | -0.24 | -15.02% |
| 2026-03-12 | 2025-12 | -2.76 | -1.78 | 0.98 | 35.51% |
| 2025-11-06 | 2025-09 | -2.85 | -1.85 | 1 | 35.09% |
| 2025-08-07 | 2025-06 | -3.13 | -2.95 | 0.18 | 5.75% |
| 2025-05-08 | 2025-03 | -2.7 | -3.3 | -0.6 | -22.22% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-11 | Wedbush | Upgrade | Neutral | Neutral |
| 2026-05-08 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2026-04-21 | Citigroup | Upgrade | Buy | Buy |
| 2026-04-21 | Wedbush | Upgrade | Neutral | Neutral |
| 2026-04-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-04-20 | BTIG | Upgrade | Buy | Buy |
Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-16 | ROBIN HOWARD W | Chief Executive Officer | 55.07K | Sale |
| 2025-11-24 | WILSON MARK ANDREW | Officer | 21.59K | Sale |
| 2026-06-29 | ZALEVSKY JONATHAN | Officer | 9.76K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR Inc | 4.30M | 0.00 | 12.74% |
| 2026-03-30 | Bvf Inc | 2.56M | 0.00 | 7.58% |
| 2026-03-30 | Two Seas Capital LP | 1.96M | 0.00 | 5.80% |
| 2026-03-30 | Vanguard Capital Management, LLC | 1.20M | 0.00 | 3.54% |
| 2025-12-30 | Vanguard Group Inc | 1.03M | 0.00 | 3.04% |
| 2026-03-30 | Two Sigma Investments LLC | 930.74K | 0.00 | 2.75% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Growth Compy Commingled Pl S | 2.32M | 0.00 | 6.86% |
| 2026-05-30 | Fidelity Growth Company Fund | 1.83M | 0.00 | 5.43% |
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 1.08M | 0.00 | 3.18% |
| 2026-06-29 | iShares Russell 2000 ETF | 901.46K | 0.00 | 2.67% |
| 2026-05-30 | Fidelity Growth Company K6 | 492.78K | 0.00 | 1.46% |
| 2026-05-30 | Fidelity Series Growth Company | 419.82K | 0.00 | 1.24% |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2025-06-09 |
| 2 : 1 | 2000-08-23 |